Taysha Gene Therapies, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -183.0% | -131.6% | -81.6% |
| FY2022 | -17,493.6% | -426.6% | -131.5% |
| FY2023 | -148.9% | -96.6% | -64.6% |
| FY2024 | -124.8% | -77.3% | -55.7% |
| FY2025 | -44.1% | -36.7% | -31.7% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -183.0% | -131.6% | -81.6% |
| FY2022 | -17,493.6% | -426.6% | -131.5% |
| FY2023 | -148.9% | -96.6% | -64.6% |
| FY2024 | -124.8% | -77.3% | -55.7% |
| FY2025 | -44.1% | -36.7% | -31.7% |